Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy.
For the last two years, the American Society of Clinical Oncology (ASCO) conference has been a reminder that even when COVID dominates headlines, amazing advances are still being made in ca
